Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

Phase 4 Completed 123 enrolled Novo Nordisk A/S

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.

Timeline

Start: 2002-03
Primary completion: 2003-08
Completion: 2003-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin aspart	Protein / enzyme biologic	—	Subcutaneous

Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

Summary

Timeline

Drugs

Indications